Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Oct 8, 2024
Product Development
Six questions raised by Scholar Rock’s standout SMA data
Add-on treatment with apitegromab met the primary endpoint in a Phase III study in patients with waning responses to SOC
BioCentury | Nov 18, 2023
Data Byte
SMA sales topping out?
After a period of rapid growth, sales of all three approved SMA products have stabilized in recent quarters
BioCentury | Jul 28, 2023
Market Access
SMA sales: Spinraza, Zolgensma and Evrysdi converge
The ASO, gene therapy and small molecule are sharing similar portions of the $1.3B market
BioCentury | Feb 2, 2023
Regulation
Feb. 1 Quick Takes: FDA approves GSK’s daprodustat
Plus: Patient Square caps first fund at $3.9B, and updates from Verily-Otsuka Novartis, Evelo, Sherlock-Sense, Recurv and more
BioCentury | Aug 25, 2022
Deals
Aug. 25 Quick Takes: Radiopharma company Aktis tops off series A
Plus Takeda’s dengue vaccine gets first global approval, and updates from Pfizer, AstriVax, Ordaos, Zelluna and more
BioCentury | Aug 5, 2022
Editor's Commentary
Letter from the Editor: new modalities to decorate your wall
A downloadable chart of approved new modalities for general use
BioCentury | Jul 20, 2022
Market Access
Novartis’ American ambitions
Can the Swiss pharma crack into the top five in the U.S. market, based on its current pipeline?
BioCentury | Jun 25, 2022
Discovery & Translation
CRISPR complex for efficient RNA knockdown; plus improving ASOs for SMA and more
BioCentury’s roundup of translational news
BioCentury | Jun 1, 2022
Finance
May 31 Quick Takes: Ultima emerges with $600M, low-cost sequencing platform
Plus Priority review for Y-mAbs’ Omblastys and updates from Avillion, TG, EW Healthcare, Regeneron, Moderna and more
Items per page:
1 - 10 of 183